Overview

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects

Status:
RECRUITING

Trial end date:
2026-07-30

Target enrollment:

Participant gender:

Summary

First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study. Part A: randomised, double-blind, placebo-controlled, single ascending dose study. Part B: open label, multiple ascending dose study.

Phase:

PHASE1

Details

Lead Sponsor:

BAR Pharmaceuticals s.r.l.

Treatments:

BAR502